Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (12134)	6/22/2004 8:51:41 AM
From: rkrw	Read Replies (1) \| Respond to of 52153

Interesting work Tuck. trca, could be a bigger market potential than you think. But will 2 injections/day be a barrier to penetrating a broader market? How many injections is HGH? I think this is where insm has an advantage, binding to the second antibody extends the duration? Also being one of the chopped ipo's they'll need cash in the next year. cgtk, more a device ala stents. I bought a smidge, but it's terribly risky. If it bombs, tax loss city. I was poking through the S1 for Momenta which is supposed to ipo this week. I met the ceo while he was at mlnm and know people who speak very highly of him and find their sugar technology to be very interesting. A true stretch for them to be public, as they have nothing in the clinic. Have spent just $5M on r&d since inception though that wouldn't include the cost of developing the tech in academia or whereever they got it. Working on an anda for lovenox with Sandoz. Yet another inhaled insulin play, but, they claim to have *99%* bioavailability in animals. Astounding if it bears out in humans. Inhaled insulin, hgh, epo listed as early programs. Biocentury a few months ago ran an interesting cover story tracking bio returns post ipo. The best returns came from the lowest market cap ipo's (<$200M) as opposed to the bigger money more hyped ipo's. So who knows, maybe a few good ones will emerge from this tepid group.